Metabolomic profiling of pancreatic adenocarcinoma reveals fundamental clinical features
J. L. IOVANNA, A. El kaoutari, N. Fraunhoffer, O. Hoare, C. Teyssedou, O. Gayet, J. Roques, G. A. Lomberk, R. A. Urrutia, N. J. Dusetti
This study identifies a metabolic signature in pancreatic adenocarcinoma that predicts clinical outcomes and drug resistance, suggesting metabolic targeting as a therapeutic strategy.
bioRxiv · Feb 1, 2021Cancer Biology